Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Standard Deflection); Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Reverse Deflection)

K260708 · Vein 360 · FGB · Oct 20, 2026 · Gastroenterology, Urology

Device Facts

Record IDK260708
Device NameVein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Standard Deflection); Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Reverse Deflection)
ApplicantVein 360
Product CodeFGB · Gastroenterology, Urology
Decision DateOct 20, 2026
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 876.1500
Device ClassClass 2
AttributesTherapeutic

Indications for Use

The Vein360 Reprocessed LithoVue Digital Flexible Ureteroscopes are intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.

Device Story

Reprocessed single-use digital flexible ureteroscope; used for visualization and access in urinary tract. Input: CMOS imager at distal tip captures raw image data; LED provides illumination. Transformation: Raw data transmitted through handle and umbilicus to LithoVue System Workstation for processing and external display output. Operation: Physician-operated in clinical setting; enables use of accessories (baskets, laser fibers, guidewires, biopsy forceps). Benefit: Facilitates diagnostic/therapeutic procedures via transurethral/percutaneous access. Reprocessing: Includes cleaning, inspection, functional testing, and EO sterilization; devices permanently marked and tracked; limited to one reprocessing cycle.

Clinical Evidence

Bench testing only. Validation included cleaning validation (removal of artificial soil), sterilization validation (EO), biocompatibility, and performance testing (simulated use, dimensional/mechanical/electrical integrity, image quality, system compatibility). No clinical data presented.

Technological Characteristics

Flexible ureteroscope with handle and shaft. Components: LED illumination, CMOS distal imager, fiber-optic light transmission. Energy: Electrical (workstation-powered). Sterilization: Ethylene Oxide (EO) gas. Connectivity: Proprietary interface for LithoVue System Workstation. Dimensions: 3.23 mm shaft diameter, 1.15 mm instrument channel. Single-use, reprocessed once.

Indications for Use

Indicated for adolescents (12-21 years) and adults (22+ years) requiring visualization of the urinary tract (urethra, bladder, ureter, calyces, renal papillae) and diagnostic or therapeutic procedures via transurethral or percutaneous access.

Regulatory Classification

Identification

An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.

Special Controls

*Classification* —(1)*Class II (special controls).* The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9.

In combination with the general controls of the FD&C Act, the integrated operating table-electromechanical surgical system is subject to the following special controls: 1. (1) Premarket clinical performance testing, or a combination of premarket clinical performance testing and postmarket surveillance (in accordance with special control (2)), must include the following: 1. (i) Objective performance measures (e.g., rate and number of conversions to other surgical modalities, rate of device related adverse events (including tissue injury, hematoma, and increased blood loss), and their severity, cause, and outcomes) must be reported with relevant descriptive comparator performance measures. 2. (ii) The data must demonstrate the performance of the device for providing accurate and precise control of attached surgical instruments in range of clinical conditions relevant to the device's intended use. 3. (iii) The test dataset must include data collected from a patient population representative of the intended patient population under anticipated conditions of use. 2. (2) Data obtained from postmarket surveillance must demonstrate, in consideration of the premarket data obtained in accordance with special control (1), that the device performs in accordance with special control (1), unless FDA determines, based on the totality of the premarket data, that data from postmarket surveillance is not required to demonstrate that the device performs as intended. Such postmarket surveillance must be conducted per a protocol determined appropriate by FDA to demonstrate that the device performs as intended (in consideration of the premarket data obtained in accordance with special control (1)), and must include initiation, enrollment, and reporting requirements to ensure timely periodic updates to FDA on post-market surveillance progress and outcomes. 3. (3) Animal performance testing must evaluate the extent of port site trauma due to repositioning of table during surgical procedures when utilizing robotic minimally invasive and laparoscopic approaches 4. (4) The device manufacturer must develop, and update as necessary, a device-specific use training program that ensures proper device setup/use/shutdown, accurate control of instruments to perform the intended surgical procedures, troubleshooting and handling during unexpected events or emergencies, and safe practices to mitigate use error. 5. (5) The device manufacturer may only distribute the device to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program. (6) Human factors assessment must demonstrate that the user can correctly use the device system across all intended use environments with the provided instructions and training materials, including patient access during normal operating conditions and emergency situations, and effects arising from the integrated nature of the operating table and robotic surgical arms. (7) Labeling must include: (i) A detailed summary of clinical performance testing conducted with the device, including study population, results, adverse events, and comparisons to any comparator groups identified; (ii) A statement in the labeling that the safety and effectiveness for the representative specific procedures was based on evaluation of the device as a surgical tool and did not include evaluation of outcomes related to the treatment of the patient's underlying disease or condition, unless FDA determines that it can be removed or modified based on clinical performance data submitted to FDA; (iii) Identification of compatible devices; (iv) The list of surgical procedures for which the device has been determined to be safe with clinical justification; (v) Reprocessing instructions for reusable components; (vi) A shelf life for any sterile components; (vii) A description of the device-specific use training program; (viii) A statement that the device is only for distribution to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program; and (ix) A summary of any completed postmarket surveillance data collected as required by special control (2), including updated labeling to accurately reflect outcomes observed in postmarket surveillance. (8) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use and must include: (i) Device motion accuracy and repeatability; (ii) System testing; (iii) Instrument reliability; (iv) Crosstalk; (v) Table motion control; (vi) Thermal effects on tissue; (vii) User-device interface performance; (viii) Workspace access testing; and (ix) Performance testing with compatible devices. (9) Software verification, validation, and hazard analysis must be performed. (10) Electromagnetic compatibility and electrical, thermal, and mechanical safety testing must be performed. (11) Performance data must demonstrate the sterility of all patient-contacting device components. (12) Performance data must support the shelf life of the device components provided sterile by demonstrating continued sterility and package integrity over the labeled shelf life. (13) Performance data must validate the reprocessing instructions for the reusable components of the device. (14) Performance data must demonstrate that all patient-contacting components of the device are biocompatible. (15) Performance data must demonstrate that all patient-contacting components of the device are non-pyrogenic. (16) The device manufacturer must submit a report to the FDA annually on the anniversary of initial marketing authorization for the device, until such time as FDA may terminate such reporting, which comprises the following information: (i) Cumulative summary, by year, of complaints and adverse events since date of initial marketing authorization; and (ii) Identification and rationale for changes made to the device, labeling, or device specific use training program, which did not require submission of a premarket notification during the reporting period.

Predicate Devices

Submission Summary (Full Text)

{1} **U.S. FOOD & DRUG** ADMINISTRATION October 20, 2026 Vein360 Suzanne Meyer CEO 4460 Lake Forest Dr., Suite 218 Cincinnati, Ohio 45242 Re: K260708 Trade/Device Name: Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Standard Deflection), Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Reverse Deflection) Regulation Number: 21 CFR 876.1500 Regulation Name: Endoscope and accessories Regulatory Class: II Product Code: FGB Dated: September 24, 2026 Received: September 24, 2026 Dear Suzanne Meyer: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: The Center for Devices and Radiological Health (CDRH) does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {2} K260708 - Suzanne Meyer Page 2 Before making any change significantly affecting the safety or effectiveness of the device, you must submit a new premarket notification in accordance with 21 CFR 807.81. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the {3} K260708 - Suzanne Meyer Page 3 Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Mark R. Kreitz -S for Mark J. Antonino, M.S. Assistant Director DHT3B: Division of Reproductive, Gynecology, and Urology Devices OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {4} K260708 - Suzanne Meyer Page 4 The following devices are included in the scope of this 510(k) premarket notification: | Device Name | OEM Model Numbers | Vein 360 Model Numbers | Description | | --- | --- | --- | --- | | Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscope (Standard Deflection) | M0067915000 | URO-LV-STD | Reprocessed LithoVue™ Digital Flexible Ureteroscope for use with LithoVue™ System Workstation | | Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscope (Reverse Deflection) | M0067915100 | URO-LV-REV | Reprocessed LithoVue™ Digital Flexible Ureteroscope for use with LithoVue™ System Workstation | {5} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K260708 | ? | | Please provide the device trade name(s). | | ? | | Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Standard Deflection); Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Reverse Deflection) | | | | Please provide your Indications for Use below. | | ? | | The Vein360 Reprocessed LithoVue Digital Flexible Ureteroscopes are intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract. | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | | Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old) ☐ Infants (29 days old to < 2 years old) ☐ Children (2 years old to < 12 years old) ☑ Adolescents (12 years old to < 22 years old) ☑ Adults (22 years old and greater) | ? | {6} K260708 Page 1 of 3 # Attachment17_510kSummary **Date Prepared:** March 4, 2026 ## Company Name / Contact Information Company: Vein360, LLC 4460 Lake Forest Drive Suite 218 Blue Ash, OH 45242 Contact: Suzanne Meyer CEO Phone: (513) 554-1300 ![img-0.jpeg](img-0.jpeg) ## Device Name | **Trade Names:** | Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscope (Standard Deflection) Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscope (Reverse Deflection) | | --- | --- | | **Common/Usual Name:** | Digital Flexible Ureteroscope | | **Regulation Number** | 21 CFR 876.1500 | | **Classification Name** | Ureteroscope and accessories, flexible/rigid | | **Classification:** | Class II | | **Device Product Code:** | FGB | ## Predicate Devices For the purpose of establishing 'substantial equivalence', the design and technological characteristics of the proposed Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscopes were compared to the following 510k cleared device. | **Trade Name:** | LithoVue™ System | | --- | --- | | **Common/Usual Name:** | Digital Flexible Ureteroscope | | **Regulation Number** | 21 CFR 876.1500 | | **Classification Name** | Ureteroscope and accessories, flexible/rigid | | **Classification:** | Class II | | **Device Product Code:** | FGB | | **510k Submitter/Holder:** | Boston Scientific Corporation, Marlborough, MA | | **510k Number/Clearance Date:** | K153049, 11/13/2015 | ## Device Description The subject devices are reprocessed single use LithoVue™ Digital Flexible Ureteroscopes (cleared under K153049). After clinical use, the predicate devices are shipped to Vein360 following established Vein360 return instructions. Upon receipt, each device undergoes a validated reprocessing cycle that includes cleaning, inspection, functional testing, packaging and sterilization using ethylene oxide (EO) gas. The subject devices are comprised of two main components: (1) a handle with articulation controls and accessory access ports, and (2) a flexible shaft portion. The devices are intended for use with the LithoVue™ System Workstation and are designed to allow physicians to access, visualize, and perform procedures in the urinary tract. The ureteroscopes enable delivery and use of accessory devices such as retrieval baskets, laser fibers, guidewires, and biopsy forceps. Page 1 of 3 {7} Attachment17_510kSummary K260708 Page 2 of 3 The subject devices provide real-time images to the physician to facilitate diagnostic and therapeutic procedures in the urinary tract. Illumination is generated by a light emitting diode (LED) located in the digital ureteroscope handle and transmitted to the distal tip lens via a fiber-optic illumination fiber. A digital Complementary Metal-Oxide-Semiconductor (CMOS) imager located in the distal tip of the ureteroscope provides raw image data from the surgical field. The raw image data is transferred from the CMOS imager through the ureteroscope handle, via the umbilicus, to the workstation for processing and output to an external display. Other than deflection orientation, the subject device models are identical in design, materials, and intended use to one another. Deflection is controlled by a reciprocal control mechanism within the handle body and does not affect the core functionality of the device. As with the predicate devices, the subject devices are intended to be used exclusively with the LithoVue™ System Workstation. Each subject device undergoes one reprocessing cycle and is permanently marked to indicate reprocessing by Vein360. ## Indications for Use The Vein360 Reprocessed LithoVue™ Digital Flexible Ureteroscopes, reverse and standard deflection, are intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract. ## Substantial Equivalence Information The Vein360 reprocessed device has the same technological characteristics (i.e., design, material, chemical composition, energy source) as the predicate device. There are no changes to the intended therapeutic, diagnostic, or surgical use of the device. The subject devices covered by the scope of this submission are substantially equivalent to the predicate devices with respect to indications for use, device design, materials, performance, and method of sterilization. As a reprocessed single use device, there are no changes to the clinical applications, patient population, or method of operation. A high-level comparison of features between the predicate and subject devices is provided below. | Feature | Predicate Devices (K153049) | Subject Devices | | --- | --- | --- | | Maximum Angle of Deflection | 270 degrees (in both directions) | Same | | Minimum Bend Radius | 8 mm | Same | | Shaft Working Length | 68 cm | Same | | Instrument Channel Length | 82 cm | Same | | Maximum Insertion Portion Width (Overall Shaft Diameter) | 3.23 mm | Same | | Minimal Instrument Channel Width | 1.15 mm | Same | | Maximum Guidewire Outside Diameter Compatibility | 0.97 mm | Same | | Field of View | 85° degrees in air | Same | | Optical Working Distance | 2 - 50 mm | Same | | Direction of View | 0° (forward viewing) | Same | | Sterilization Method | Ethylene Oxide (EO) gas | Same | Page 2 of 3 {8} Attachment17_510kSummary K260708 Page 3 of 3 | Feature | Predicate Devices (K153049) | Subject Devices | | --- | --- | --- | | Shelf Life | Unknown | 13 months | | Uses | Single patient use | Same | | Accessories | None | Same | | Reprocessing Mark Indicator | None | Indelible mark (line) on power connector | ## Cleaning Validation Comprehensive cleaning validation studies were performed using clinically used subject devices that were subsequently soiled with artificial test soil. The cleaning process was validated by objectively demonstrating complete removal of physical soil under the defined minimum operating conditions. Supporting data for the cleaning process and its validation are included in this submission. ## Performance Validation Performance validation studies were performed after ensuring subject devices were clinically used and then soiled with artificial test soils. The cleaning process was performed under conditions intentionally selected to impose the greatest potential stress on the devices, including the longest exposure times and highest chemical concentrations, in order to maximally challenge device functional performance. Electro-mechanical performance testing was performed to demonstrate that the reprocessing operations did not adversely affect the predicate device's form, fit, or function. Bench and laboratory testing included: - Cleaning Validation - Sterilization Validation - Biocompatibility - Performance Validation - Simulated Use - Dimensional Integrity - Mechanical integrity - Image Quality - Electrical Integrity - Electrical Safety - System Compatibility - Packaging Validation Performance testing demonstrated that the subject devices are substantially equivalent to the predicate device for their intended use. The subject devices were validated for one reprocessing cycle following completion of performance testing. The subject devices are permanently marked and tracked using unique serial numbers applied by Vein360 during the reprocessing cycle. Devices are removed from service and excluded from further reprocessing once they reach the maximum allowable number of reprocessing cycles. In addition, Vein360 limits reprocessing exclusively to devices with no prior reprocessing history and does not accept devices previously reprocessed by other reprocessors. ## Conclusion Vein360 concludes the subject devices are as safe, as effective, and perform as well as the predicate devices. Page 3 of 3
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...